Zheng BQ, Wang ZP, Feng RZ, Zheng ZC, Wang HJ, Wang H, Tuo HF. Large cell neuroendocrine carcinoma of the distal common bile duct: A case report and literature review. World J Clin Cases 2026; 14(24): 123303 [DOI: 10.12998/wjcc.123303]
Corresponding Author of This Article
Hong-Fang Tuo, Associate Professor, Second Department of Hepatobiliary and Pancreatic Surgery, Hebei Provincial People’s Hospital, No. 348 Heping West Road, Xinhua District, Shijiazhuang 050051, Hebei Province, China. tuohongfang2023@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
case-report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Zheng BQ, Wang ZP, Feng RZ, Zheng ZC, Wang HJ, Wang H, Tuo HF. Large cell neuroendocrine carcinoma of the distal common bile duct: A case report and literature review. World J Clin Cases 2026; 14(24): 123303 [DOI: 10.12998/wjcc.123303]
Bo-Qian Zheng, Ze-Cun Zheng, Hao Wang, Graduate School, Hebei Medical University, Shijiazhuang 050051, Hebei Province, China
Ze-Pu Wang, Department of Hepatobiliary and Pancreatic Surgery II, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China
Rui-Zeng Feng, Hong-Jie Wang, Graduate School, Hebei North University, Zhangjiakou 075000, Hebei Province, China
Hong-Fang Tuo, Second Department of Hepatobiliary and Pancreatic Surgery, Hebei Provincial People’s Hospital, Shijiazhuang 050051, Hebei Province, China
Author contributions: Wang ZP was responsible for manuscript drafting, data collection, and literature review; Zheng BQ performed pathological analysis and interpretation and contributed to manuscript drafting; Tuo HF was responsible for study conception, supervision, and final approval; Wang H, Feng RZ, and Zheng ZC contributed to the supplementation of key references; Wang HJ prepared the figures; all authors have read and approved the final manuscript.
AI contribution statement: AI tools were not used for any part of the scientific content, analysis, or writing of this manuscript. The authors assume full responsibility for the integrity, accuracy, and originality of the work.
Informed consent statement: Written informed consent was obtained from the patient for the publication of this case report and the accompanying images.
Conflict-of-interest statement: All authors declare that they have no conflicts of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised in accordance with the CARE Checklist (2016).
Corresponding author: Hong-Fang Tuo, Associate Professor, Second Department of Hepatobiliary and Pancreatic Surgery, Hebei Provincial People’s Hospital, No. 348 Heping West Road, Xinhua District, Shijiazhuang 050051, Hebei Province, China. tuohongfang2023@163.com
Received: May 18, 2026 Revised: June 18, 2026 Accepted: August 5, 2026 Published online: August 26, 2026 Processing time: 96 Days and 8.9 Hours
Core Tip
Core Tip: This case report describes a distal common bile duct large cell neuroendocrine carcinoma (LCNEC) with a positive bile duct margin (R1 resection). Comprehensive immunohistochemistry revealed a proficient mismatch repair (MMR)/microsatellite stable phenotype, providing a molecular basis for excluding postoperative adjuvant immunotherapy. This is the first report of MMR testing directly guiding treatment decisions in biliary LCNEC, and clinicians are advised to incorporate MMR testing as a routine examination for biliary neuroendocrine carcinoma to inform immunotherapy decisions. With effective systemic therapy, positive margin (R1) resection does not preclude the possibility of favorable short-term outcomes. Multidisciplinary management that integrates molecular pathology is key to individualized treatment of rare tumors.
